IIIA-B stádiumú NSCLC elsovonalbeli Taxotere-Cisplatin konkuráló kemo-radioterápiájának eredményei 42 irreszekábilis daganatos beteg vizsgálata alapján

Translated title of the contribution: Results on 42 irresectable NSCLC IIA-B patients with initial concurrent Taxotere-Cisplatin chemoradiotherapy

Mária Szilasi, Ákos Horváth, Tamás Dolinay, János Szántó, László Brugós, László Lengyel, S. Kiss Sándor, Magdolna Kiss, Zsolt Adamecz

Research output: Contribution to journalArticle

Abstract

Goals: A prospective multicenter study to treat non-small cell lung cancer (NSCLC) with inductive chemoradiotherapy for improving chances of operability. If used as first-line therapy, combined treatment improves survival and it is well tolerated with a low rate of side effects. Patients: 42 patiens with stage IIIA-B NSCLC from which 36 could be followed. Methods: A full dose Taxotere-Cisplatin chemotherapy was given to patients with concurrent radiotherapy in 2 Gy fractions up to 60 Gy via conformal irradiation. Results: Local response was very high and 40.47% of patients became operable while in inoperable cases consolidation chemotherapy showed similar results as other protocols. We also found a low rate of side effects. The high rate of brain metastasis suggests that prophylactic cranial irradiation (PCI) should be considered.

Original languageHungarian
Pages (from-to)233-236
Number of pages4
JournalMagyar onkologia
Volume50
Issue number3
Publication statusPublished - Dec 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Szilasi, M., Horváth, Á., Dolinay, T., Szántó, J., Brugós, L., Lengyel, L., Sándor, S. K., Kiss, M., & Adamecz, Z. (2006). IIIA-B stádiumú NSCLC elsovonalbeli Taxotere-Cisplatin konkuráló kemo-radioterápiájának eredményei 42 irreszekábilis daganatos beteg vizsgálata alapján. Magyar onkologia, 50(3), 233-236.